insitro Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 321

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $400M

  • Investors
  • 24

insitro General Information

Description

Operator of a data-driven drug discovery and development company intended to transform how drugs are discovered and delivered to patients. The company uses machine learning and high-throughput biology to create massive data sets to be brought to bear on key bottlenecks in pharmaceutical R&D, enabling drug development companies to have predictive models that are used to accelerate target selection, design, and develop effective therapeutics, and to inform clinical strategy.

Contact Information

Website
www.insitro.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 279 East Grand Avenue
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Vertical(s)
Big Data, Artificial Intelligence & Machine Learning, TMT
Corporate Office
  • 279 East Grand Avenue
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

insitro Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 07-Apr-2021 $400M Completed Product Development
2. Early Stage VC (Series B) 26-May-2020 Completed Product Development
1. Early Stage VC (Series A) 01-May-2018 $100M $100M Completed Product Development
To view insitro’s complete valuation and funding history, request access »

insitro Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A2 18,359,806 $0.000010 8% $2.69 $2.69 1x $2.69 13.43%
Series A1 33,327,366 $0.000010 8% $0.9 $0.9 1x $0.9 24.38%
To view insitro’s complete cap table history, request access »

insitro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a data-driven drug discovery and development company intended to transform how drugs are discovered and deli
Drug Discovery
South San Francisco, CA
321 As of 2024

Oxford, United Kingdom
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

insitro Competitors (4)

One of insitro’s 4 competitors is Exscientia, a Pending Transaction (M&A) company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exscientia Pending Transaction (M&A) Oxford, United Kingdom
Verge Genomics Venture Capital-Backed South San Francisco, CA
Atomwise Venture Capital-Backed San Francisco, CA
Recursion Pharmaceuticals Formerly VC-backed Salt Lake City, UT
To view insitro’s complete competitors history, request access »

insitro Patents

  • 48

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 39

    Pending

  • Expiring in next 12 mo

insitro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240386566-A1 Cellular time-series imaging, modeling, and analysis system Pending 18-May-2023
US-20240386990-A1 Predicting cellular responses to perturbations Pending 18-May-2023
US-20240395415-A1 Cellular time-series imaging, modeling, and analysis system Pending 18-May-2023
US-20240294863-A1 Autonomous maintenance and differentiation of induced pluripotency cells Pending 02-Mar-2023
US-20240273718-A1 Machine-learning-enabled predictive biomarker discovery and patient stratification using standard-of-care data Pending 15-Feb-2023 G06T7/0012
To view insitro’s complete patent history, request access »

insitro Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

insitro Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
ADS Ventures Venture Capital Minority
Globalive Capital Family Office Minority
HBM Genomics Venture Capital Minority
RONA Holdings Venture Capital Minority
SoftBank Investment Advisers Growth/Expansion Minority
You’re viewing 5 of 24 investors. Get the full list »

insitro Acquisitions (1)

insitro’s most recent deal was a Merger/Acquisition with Haystack Sciences. The deal was made on 22-Oct-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Haystack Sciences 22-Oct-2020 Merger/Acquisition Drug Discovery
To view insitro’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

insitro FAQs

  • When was insitro founded?

    insitro was founded in 2018.

  • Where is insitro headquartered?

    insitro is headquartered in South San Francisco, CA.

  • What is the size of insitro?

    insitro has 321 total employees.

  • What industry is insitro in?

    insitro’s primary industry is Drug Discovery.

  • Is insitro a private or public company?

    insitro is a Private company.

  • What is the current valuation of insitro?

    The current valuation of insitro is .

  • What is insitro’s current revenue?

    The current revenue for insitro is .

  • How much funding has insitro raised over time?

    insitro has raised $643M.

  • Who are insitro’s investors?

    ADS Ventures, Globalive Capital, HBM Genomics, RONA Holdings, and SoftBank Investment Advisers are 5 of 24 investors who have invested in insitro.

  • Who are insitro’s competitors?

    Exscientia, Verge Genomics, Atomwise, and Recursion Pharmaceuticals are competitors of insitro.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »